Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model.
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis; D001932:Brain Neoplasms / Q000628:therapy*; D053148:Caspase 3; D020169:Caspases / Q000096:biosynthesis; D002455:Cell Division; D045744:Cell Line, Tumor; D002470:Cell Survival; D043169:Endostatins / Q000378:metabolism / Q000494:pharmacology; D005909:Glioblastoma / Q000628:therapy*; D005910:Glioma / Q000473:pathology / Q000628:therapy; D006801:Humans; D019394:Ki-67 Antigen / Q000096:biosynthesis; D008279:Magnetic Resonance Imaging; D051379:Mice; D008819:Mice, Nude; D008833:Microcirculation; D009368:Neoplasm Transplantation; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000096:biosynthesis; D013687:Telencephalon / Q000473:pathology; D013997:Time Factors; D023041:Xenograft Model Antitumor Assays
D020533:Angiogenesis Inhibitors; D043169:Endostatins; D019394:Ki-67 Antigen; D019408:Platelet Endothelial Cell Adhesion Molecule-1; C505407:CASP3 protein, human; C505409:Casp3 protein, mouse; D053148:Caspase 3; D020169:Caspases